Q4 2024 Management View Bob Harrison, CEO, highlighted that the Hawaii economy continues to expand at a slow pace, with ...

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

China could be leading the charge, but the US, Canada, and Europe won’t be far behind.

Q4 2024 Management View CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and ...

Discretionary categories like luxury and big ticket home purchases performed disproportionately poorly as inflation remained ...

Microsoft announces Small, Medium Enterprises and Channel, SME&C, headed by President Ralph Haupter, replaced as EMEA leader ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

General Dynamics faces challenges in the aerospace and submarine segments, impacting performance, but growth expected, ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

CEO Mikael Bratt highlighted a record-breaking quarter with all-time highs in operating profit, operating margin, and earnings per share, despite a 5% year-over-year decrease in sales due to currency ...

“Our record revenue and strong operating margins drove EPS to a new all-time record with double-digit growth and allowed us ...